Open Label, Randomized, Single-dose, Cross-over Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Tablets, Administered to Adult Male and Female Patients With Chagas' Diseasee

Trial Profile

Open Label, Randomized, Single-dose, Cross-over Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Tablets, Administered to Adult Male and Female Patients With Chagas' Diseasee

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Nifurtimox (Primary)
  • Indications Chagas disease
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 28 Feb 2018 Planned primary completion date changed from 1 Aug 2018 to 12 Jul 2018.
    • 28 Feb 2018 Planned initiation date changed from 2 Mar 2018 to 2 May 2018.
    • 23 Jan 2018 Planned End Date changed from 30 Jul 2018 to 3 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top